secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001437749-24-016260
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences stockholders elect three directors, ratify auditor, approve say-on-pay at 2024 annual meeting
--------------------------------------------------------------------------------

- Quorum of ~62% (26,979,468 shares) represented at May 9, 2024 annual meeting.
- Three director nominees elected: Barbier (10.8M for), Robertson (8.9M for), Scannon (10.9M for).
- Ratification of Ernst & Young as auditor approved (26.5M for, 0.4M against).
- Advisory vote on 2023 executive compensation approved (9.4M for, 1.3M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/sava20240513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer